CSL reported net income after tax of $1.76 billion in the first half of 2022. Sales of the leading recombinant hemophilia B product increased 17%. The perioperative bleeding product increased 15%. The transformative therapy for patients with hereditary angioedema (HAE) increased by 7%. HPV royalties increased 134%. The influenza vaccine business, Seqirus, delivered another strong performance with sales up 17%.
" CSL has delivered a result in line with our expectations in a challenging environment brought about by the ongoing impacts of the global COVID pandemic. Despite the additional challenges posed by the latest COVID variant - Omikron - I am very proud of the way the company has responded and remain optimistic about the future. "
Paul Perreault, Chief Executive Officer and Managing Director of CSL
